RxDoctor Payments Data

Rachel Conklin, PA

Physician Assistant · Nashville, TNNPI 1861829053

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $45,947 of the $59,881 with a category attached, or 76.7%. Johnson & Johnson accounts for 98.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $50,666, more than ten times the $74 reported in 2021. Among physician assistant clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,881in general payments, 2019–2025

Across 112 payments — averaging $534.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$59K
  • AbbVie$361
  • Regeneron Healthcare Solutions, Inc.$129
  • Pfizer$74
  • Gilead$72
  • Takeda Pharmaceuticals U.S.A., Inc.$66
  • plus $161 from 5 others

What the payments were for

  • Speaking & faculty fees$45,94777%
  • Travel & lodging$11,43519%
  • Food & beverage$2,3494%
  • Education$1500%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,881 in reported general payments places this provider in the 95th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$9,507
Medicare patients
61
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$410,412
LinzessLinaclotide18$9,542
Colestipol Hcl21$2,387
Budesonide DrBudesonide23$2,347
Pantoprazole Sodium144$2,325
Omeprazole47$987
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg13$335
Dicyclomine Hcl13$299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$59,019$410,41215 claims
AbbVieLinzess$361$9,54218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →